Novo Nordisk A/S (NYSE:NVO) Raised to “Neutral” at BNP Paribas Exane

Novo Nordisk A/S (NYSE:NVO) was upgraded by BNP Paribas Exane from an “underperform” rating to a “neutral” rating in a research note issued to investors on Wednesday, Marketbeat reports. The brokerage presently has a $54.00 target price on the stock. BNP Paribas Exane’s target price would suggest a potential upside of 6.05% from the stock’s previous close.

NVO has been the topic of several other reports. Hsbc Global Res downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 31st. UBS Group lowered Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Barclays reiterated an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. HSBC lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $57.00 target price for the company. in a research note on Thursday, July 31st. Finally, Guggenheim lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $83.75.

Novo Nordisk A/S Trading Up 0.0%

Shares of NVO stock opened at $50.92 on Wednesday. The business’s fifty day moving average price is $65.40 and its 200 day moving average price is $70.66. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $139.74. The firm has a market capitalization of $227.35 billion, a PE ratio of 13.99, a P/E/G ratio of 1.75 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Novo Nordisk A/S

Hedge funds have recently bought and sold shares of the business. Strategic Investment Solutions Inc. IL lifted its holdings in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after buying an additional 300 shares during the last quarter. Copeland Capital Management LLC lifted its holdings in Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after buying an additional 255 shares during the last quarter. North Capital Inc. bought a new position in Novo Nordisk A/S during the 1st quarter worth approximately $27,000. Park Square Financial Group LLC bought a new position in Novo Nordisk A/S during the 4th quarter worth approximately $29,000. Finally, Stone House Investment Management LLC bought a new position in Novo Nordisk A/S during the 1st quarter worth approximately $30,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.